Cross-Sector entity
BPC-157 is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is regulation: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention Vanta Holdings Inc., all published on August 1, 2026.
3 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
BPC-157 is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is regulation: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention Vanta Holdings Inc., all published on August 1, 2026. Each carries 2 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vanta Holdings Inc.. Shared-story counts are live from our verified record — not editorial picks.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
A key FDA panel vote could expand legal access to BPC-157, TB-500, and four other peptides through compounding pharmacies. Vanta is positioning its telehealth and pharmacy network to deliver these therapies to consumers seeking longevity care.
The FDA advisory committee recommended six peptide substances for the 503A Bulks List, a critical regulatory step that could reshape compounding pharmacy law. Vanta is proactively building a compliant telehealth and manufacturing infrastructure, anticipating the rule change.
Source: tennesseedaily.com · californiatelegraph.com
